Open AccessJournal Article
Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients.
Mark W. Pasmantier,Morton Coleman,Richard T. Silver,Aurora P. Mamaril,Cirila C. Quiguyan,Galindo A +5 more
Reads0
Chats0
TLDR
Doxorubicin and cisplatin combination therapy is effective with acceptable toxicity in patients with advanced endometrial carcinoma and is readily administered on an outpatient basis with comparatively low major toxic effects.Abstract:
Sixteen patients with advanced (International Federation of Gynecology and Obstetrics stage III and IV) adenocarcinoma of the endometrium were treated with twelve 28-day cycles of doxorubicin and cisplatin. Response was achieved in 92% of patients (11 responses among 12 patients) who had received no prior chemotherapy and in 50% (two responses among four patients) of previously treated patients. Median survival was 10 months. Doxorubicin and cisplatin were readily administered on an outpatient basis with comparatively low major toxic effects, primarily hematologic, renal, and gastrointestinal. These results indicate that doxorubicin and cisplatin combination therapy is effective with acceptable toxicity in patients with advanced endometrial carcinoma.read more
Citations
More filters
Journal ArticleDOI
Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II Study
Paul Hoskins,Kenneth D. Swenerton,J.A. Pike,Frances M.P. Wong,Peter Lim,Christina Acquino-Parsons,Nhu Lee +6 more
TL;DR: Carboplatin-paclitaxel is an efficacious, low-toxicity regimen for managing primarily advanced or recurrent endometrial cancers.
Journal ArticleDOI
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
Matti Aapro,F H van Wijk,Giorgio Bolis,B. Chevallier,M.E.L. van der Burg,Andres Poveda,C.F. de Oliveira,Salvatore Tumolo,Scotto di Palumbo,Martine Piccart,M Franchi,Flavia Zanaboni,A. J. Lacave,R. Fontanelli,G. Favalli,Paolo Zola,Jean-Paul Guastalla,Riccardo Rosso,Christian Marth,M Nooij,M. Presti,C Scarabelli,Ted A.W. Splinter,E. Ploch,Louk V.A.M. Beex,W.W. ten Bokkel Huinink,M. Forni,M. Melpignano,P. Blake,Pierre Kerbrat,Cesar Mendiola,Andrés Cervantes,A. Goupil,Peter Harper,C. Madronal,Moïse Namer,Giovanna Scarfone,J. E. G. M. Stoot,I. Teodorovic,Corneel Coens,Ignace Vergote,Jan B. Vermorken +41 more
TL;DR: In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status.
Journal ArticleDOI
Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration
CE Humber,Jayne F. Tierney,R.P Symonds,Mandy Collingwood,J. Kirwan,Chris Williams,John Green +6 more
TL;DR: While no one drug or regimen offers a clear benefit for women with advanced endometrial cancer, platinum drugs, anthracyclines and paclitaxel seem the most promising agents.
Journal ArticleDOI
Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma
TL;DR: It is suggested that more-intense chemotherapy regimens may improve both OS and PFS for women with advanced or recurrent endometrial cancer, however, owing to inconsistencies between cytotoxic drug combinations that have been assessed in randomised trials to date, the optimum regimen has still to be defined.
Journal ArticleDOI
Systemic therapy in metastatic or recurrent endometrial cancer.
TL;DR: The addition of paclitaxel to cisplatin plus doxorubicin appears to improve response rates, progression-free survival and overall survival, but to worsen toxicity profile.